Cognitive effects of creatine monohydrate adjunctive therapy in patients with bipolar depression: Results from a randomized, double-blind, placebo-controlled trial

Imagem de Miniatura
Arquivos
art_TONIOLO_Cognitive_effects_of_creatine_monohydrate_adjunctive_therapy_in_2017.PDF (253.38 KB)
Citações na Scopus
18
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE BV
Autores
Citação
JOURNAL OF AFFECTIVE DISORDERS, v.224, Special Issue, p.69-75, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Depressive episodes and cognitive impairment are major causes of morbidity and dysfunction in individuals suffering from bipolar disorder (BD). Novel treatment approaches that target clinical and cognitive aspects of bipolar depression are needed, and research on pathophysiology suggests that mitochondrial modulators such as the nutraceutical creatine monohydrate might have a therapeutic role for this condition. Methods: Eighteen (N=18) patients with bipolar depression according to DSM-IV criteria who were enrollled in a 6-week, randomized, double-blind, placebo-controlled trial of creatine monohydrate 6 g daily as adjunctive therapy were submitted to neuropsychological assessments (Wisconsin Card Sorting Test, Digit Span subtest of the Wechsler Adult Intelligence Scale-Third Edition, Stroop Color-Word Test, Rey-Osterrieth complex figure test, FAS Verbal Fluency Test) at baseline and week 6. Results: There was a statistically significant difference between the treatment groups of the change on the total scores after 6 weeks in the verbal fluency test, with improvement in the group receiving adjunctive treatment with creatine. We did not find significant differences between the groups of the changes on other neuropsychological tests. Limitations: Small sample and lack of a control group of healthy subjects. Conclusions: Our trial, which was the first to investigate the cognitive effects of creatine monohydrate on bipolar depression, indicates that supplementation with this nutraceutical for 6 weeks is associated with improvement in verbal fluency tests in patients with this condition.
Palavras-chave
Bipolar disorder, Depression, Cognition, Adjunctive therapy, Creatine monohydrate, Randomized controlled trial
URI
https://observatorio.fm.usp.br/handle/OPI/24342
Referências
  1. Arts B, 2008, PSYCHOL MED, V38, P771, DOI 10.1017/S0033291707001675
  2. Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548
  3. Balanza-Martinez V, 2010, EUR J PHARMACOL, V626, P87, DOI 10.1016/j.ejphar.2009.10.018
  4. Bauer IE, 2015, J PSYCHIATR RES, V62, P115, DOI 10.1016/j.jpsychires.2015.01.008
  5. Bauer M, 2015, INT J BIPOLAR DISORD, V3, DOI 10.1186/s40345-015-0029-x
  6. Bearden CE, 2001, BIPOLAR DISORD, V3, P106, DOI 10.1034/j.1399-5618.2001.030302.x
  7. Benkert O, 1997, J NERV MENT DIS, V185, P151, DOI 10.1097/00005053-199703000-00004
  8. Berk M, 2011, NEUROSCI BIOBEHAV R, V35, P804, DOI 10.1016/j.neubiorev.2010.10.001
  9. Bora E, 2009, J AFFECT DISORDERS, V113, P1, DOI 10.1016/j.jad.2008.06.009
  10. Clay HB, 2011, INT J DEV NEUROSCI, V29, P311, DOI 10.1016/j.ijdevneu.2010.08.007
  11. de Almeida KM, 2012, CNS NEUROSCI THER, V18, P160, DOI 10.1111/j.1755-5949.2011.00240.x
  12. Dechent P, 1999, AM J PHYSIOL-REG I, V277, pR698
  13. Depp CA, 2016, PSYCHIAT CLIN N AM, V39, P95, DOI 10.1016/j.psc.2015.09.004
  14. Depp CA, 2012, BIPOLAR DISORD, V14, P217, DOI 10.1111/j.1399-5618.2012.01011.x
  15. Depp CA, 2012, J AFFECT DISORDERS, V136, P812, DOI 10.1016/j.jad.2011.09.035
  16. First M, 1996, STRUCTURED CLIN INTE
  17. Goodwin GM, 2008, EUR NEUROPSYCHOPHARM, V18, P787, DOI 10.1016/j.euroneuro.2008.07.005
  18. Guy W., ECDEU ASSESSMENT MAN
  19. HAMILTON M, 1967, BRIT J SOC CLIN PSYC, V6, P278
  20. Hammett ST, 2010, NEUROSCI LETT, V479, P201, DOI 10.1016/j.neulet.2010.05.054
  21. Heaton R., 1981, WISCONSIN CARD SORTI
  22. Hu XP, 2012, NEUROIMAGE, V62, P1103, DOI 10.1016/j.neuroimage.2012.03.005
  23. Jager R, 2011, AMINO ACIDS, V40, P1369, DOI 10.1007/s00726-011-0874-6
  24. Judd LL, 2003, INT J NEUROPSYCHOPH, V6, P127, DOI 10.1017/S1461145703003341
  25. Judd LL, 2002, ARCH GEN PSYCHIAT, V59, P530, DOI 10.1001/archpsyc.59.6.530
  26. Kalra EK, 2003, AAPS PHARMSCI, V5
  27. Kato T, 1996, J NEUROPSYCH CLIN N, V8, P417
  28. Kay L, 2000, J BIOL CHEM, V275, P6937, DOI 10.1074/jbc.275.10.6937
  29. Ke Y, 2000, PSYCHIAT RES-NEUROIM, V100, P169, DOI 10.1016/S0925-4927(00)00075-5
  30. Kemp DE, 2014, J AFFECT DISORDERS, V169, pS34, DOI 10.1016/S0165-0327(14)70007-2
  31. Kemp DE, 2010, BIPOLAR DISORD, V12, P404, DOI 10.1111/j.1399-5618.2010.00823.x
  32. Kurtz MM, 2009, NEUROPSYCHOLOGY, V23, P551, DOI 10.1037/a0016277
  33. Ling J, 2009, BEHAV PHARMACOL, V20, P673, DOI 10.1097/FBP.0b013e3283323c2a
  34. Lyoo IK, 2003, PSYCHIAT RES-NEUROIM, V123, P87, DOI 10.1016/S0925-4927(03)00046-5
  35. Lyoo IK, 2012, AM J PSYCHIAT, V169, P937, DOI 10.1176/appi.ajp.2012.12010009
  36. McMorris T, 2006, PSYCHOPHARMACOLOGY, V185, P93, DOI 10.1007/s00213-005-0269-z
  37. MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382
  38. Nierenberg AA, 2013, AUST NZ J PSYCHIAT, V47, P26, DOI 10.1177/0004867412449303
  39. Nortje G, 2013, J AFFECT DISORDERS, V150, P192, DOI 10.1016/j.jad.2013.05.034
  40. Ohtsuki S, 2002, J CEREBR BLOOD F MET, V22, P1327, DOI 10.1097/01.WCB.0000033966.83623.7D
  41. Post RM, 2010, J CLIN PSYCHIAT, V71, P1176, DOI 10.4088/JCP.08m04811yel
  42. Quraishi S, 2002, J AFFECT DISORDERS, V72, P209, DOI 10.1016/S0165-0327(02)00091-5
  43. Rae C, 2003, DEV NEUROSCI-BASEL, V25, P324, DOI 10.1159/000073509
  44. Rae C, 2003, P ROY SOC B-BIOL SCI, V270, P2147, DOI 10.1098/rspb.2003.2492
  45. Rae CD, 2015, NEUROCHEM INT, V89, P249, DOI 10.1016/j.neuint.2015.08.010
  46. Rakofsky JJ, 2011, CNS SPECTRUMS, V16, P11, DOI 10.1017/S1092852912000119
  47. Rango M, 1997, MAGNET RESON MED, V38, P878, DOI 10.1002/mrm.1910380605
  48. Rawson ES, 2008, PHYSIOL BEHAV, V95, P130, DOI 10.1016/j.physbeh.2008.05.009
  49. Rey A, 1999, REVISAO TECNICA TRAD
  50. Robinson LJ, 2006, J AFFECT DISORDERS, V93, P105, DOI 10.1016/j.jad.2006.02.016
  51. Alves CRR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076301
  52. Rosa Adriane R, 2007, Clin Pract Epidemiol Ment Health, V3, P5, DOI 10.1186/1745-0179-3-5
  53. SAPPEYMARINIER D, 1992, J CEREBR BLOOD F MET, V12, P584
  54. Sarris J, 2016, AM J PSYCHIAT, V173, P575, DOI 10.1176/appi.ajp.2016.15091228
  55. Sarris J, 2015, WORLD PSYCHIATRY, V14, P370, DOI 10.1002/wps.20223
  56. Sarris J, 2011, BIPOLAR DISORD, V13, P454, DOI 10.1111/j.1399-5618.2011.00945.x
  57. Schlattner U, 2006, BBA-MOL BASIS DIS, V1762, P164, DOI 10.1016/j.bbadis.2005.09.004
  58. Serretti A, 2013, J PSYCHOPHARMACOL, V27, P616, DOI 10.1177/0269881113485143
  59. SILVER IA, 1994, J NEUROSCI, V14, P5068
  60. Spreen O, 1998, COMPENDIUM NEUROPSYC, P213
  61. Sylvia LG, 2011, J PSYCHIATR PRACT, V17, P224, DOI 10.1097/01.pra.0000398419.82362.32
  62. Torres IJ, 2007, ACTA PSYCHIAT SCAND, V116, P17, DOI 10.1111/j.1600-0447.2007.01055.x
  63. Turner CE, 2015, J NEUROSCI, V35, P1773, DOI 10.1523/JNEUROSCI.3113-14.2015
  64. WALLIMANN T, 1992, BIOCHEM J, V281, P21
  65. Watanabe A, 2002, NEUROSCI RES, V42, P279, DOI 10.1016/S0168-0102(02)00007-X
  66. Wechsler D, 2011, TEX WASI 2 WECHSLER
  67. Wechsler D, 1997, WAIS 3 ADM SCOR MAN
  68. Wyss M, 2000, PHYSIOL REV, V80, P1107
  69. YOUNG RC, 1978, BRIT J PSYCHIAT, V133, P429, DOI 10.1192/bjp.133.5.429
  70. Zahodne LB, 2014, J AM GERIATR SOC, V62, P130, DOI 10.1111/jgs.12600

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/21